Overview

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study).
Phase:
Phase 2
Details
Lead Sponsor:
PDL BioPharma, Inc.